ARVN•benzinga•
Arvinas And Pfizer Announced Topline Results From The Phase 3 VERITAC-2 Trial Of Vepdegestrant Monotherapy Versus Fulvestrant In Adults With Advanced Or Metastatic Breast Cancer, The Trial Met Its Primary Endpoint Demonstrating A Statistically Significant
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 11, 2025 by benzinga